Menu
Menu
Kwality Pharmaceuticals has secured SAHPRA approval for its Tamoxifen tablet, a significant step in expanding its oncology product range. This approval enhances the company's presence in global markets, especially in South Africa, and reinforces its commitment to providing high-quality cancer treatments.
Bajaj Healthcare’s stock surged to a 52-week high after its API manufacturing facility in Vadodara, Gujarat, received approval from Australia’s Therapeutic Goods Administration (TGA). This regulatory nod opens up new opportunities in the Australian and New Zealand markets, strengthening the company's global footprint and paving the way for increased CDMO contracts. With strong financial results, Bajaj Healthcare is poised for continued growth and success in the pharmaceutical industry.